Key Takeaways
- Steady execution, margin expansion: Revenue grew ~3.3% QoQ while EBITDA margin expanded 50 bps to 15.8%, absorbing a full-quarter wage hike and the loss of a one-time fee.
- A $271 mn TCV quarter, headlined by a $100 mn+ deal: A 5-year, Fortune 500 application modernization and cloud win from an existing client displaced a competitor and anchors a 21% TCV increase over the preceding nine months.
- The new COO and a revamped incentive structure signal a performance pivot: Compensation now ties to both revenue and profitability, hunting commissions for new logos are richer, and a cash-plus-stock LTI plan is in place.
- Management is in explicit investment mode: The medium-term margin band is 15.5%–16.5%, with 1–2% of margin deliberately reinvested into tech transformation and a domain-led sales organization over the next 24 months.
- What to watch next quarter: Whether the muted Q3 (furloughs, shorter quarter) stays within the typical range, the pace of the healthcare turnaround, and any sign that the large deal pipeline converts.
The Quarter: Growth, Margins & the Invacare Overhang
- Revenue engine: Growth was broad-based, driven by sustained account mining and the ramp-up of already secured deals. The top 20 accounts grew ahead of the company average for the third consecutive quarter.
- Margin walk: The 50 bps QoQ EBITDA expansion to 15.8% was delivered despite a full-quarter impact from the September 1st compensation hike and promotion cycle, the absence of a one-time Invacare disengagement fee, and continued investments. Operational efficiencies, higher utilization, and SG&A optimization offset those headwinds.
- Invacare distortion: The Invacare disengagement created a tough year-over-year comparison that depressed reported growth in ERP and infrastructure service lines and caused a sharp QoQ margin decline in the Life Sciences segment. Adjusted for Invacare, both ERP and infrastructure grew.
- Other expenses: A 10% sequential increase in other expenses was driven by subcontractor costs, additional working days in Q2, and niche skills staffed through subcontractors.
- Account pruning continues: The long tail of accounts was reduced from 285 to 278, with focus concentrated on the top 40, top 60, and top 200 accounts for future growth.
Guha: "I don't want to kind of be penny wise and pound foolish. I want to invest in the business because we are here to create a business for the next decade."
The $271 Mn Deal Win & Pipeline
- The headline deal: A 5-year, $100 mn+ TCV contract from an existing Fortune 500 client in North America for application maintenance, modernization, cloud migration, customer experience, data governance and analytics. The win displaced an incumbent competitor.
- Revenue timing: The deal carries a transition period of nearly six months, so material revenue uptake is expected from April onwards.
- Pipeline quality: Management confirmed more $100 mn deals sit in the pipeline, but declined to predict whether they will close in the next couple of quarters, calling it a function of client decision timelines.
- Conversion confidence: TCV signings are up 21% over the preceding nine months, and the order book is converting to revenue, evidenced by consistent 3%–3.5% quarterly growth over the last three to four quarters. Management is not seeing a "leaky bucket" of projects closing or people ramping down.
Guha: "Do we have more $100 million deals in the pipeline? Well, yes, we do have $100 million deals in the pipeline. Will it close in our favor or whether it will close in the next couple of quarters? Again, very hard for me to say... it is a manifestation of what the client wants to do."
Vertical & Service-Line Performance
| Vertical / Service Line | Trend | Commentary |
|---|---|---|
| BFSI | ▲ Strong | Grew 5.3% QoQ; company is investing and very bullish, though Q3 will see furlough impact. |
| Manufacturing | ▲ Strong | Grew 4.2% QoQ; a key growth driver alongside BFSI. |
| Healthcare / Life Sciences | ▼ Soft | Softness expected to bounce back; company is investing for a turnaround and margin improvement. |
| Energy & Utilities | ▼ Soft | Softness described as an industry trend; management cannot predict when it will turn around. |
| Digital & Cloud | ▲ Strong | Strong sequential and YoY growth; Microsoft business is a large, solidly growing component. Data & Analytics showing signs of revival. |
| ERP | ▬ Bottoming out | Adjusted for Invacare, grew ~1% QoQ and has "bottomed out." Bullishness driven by the SAP S/4HANA 2027 migration deadline, JDE capability, and the mid-tier manufacturing segment in North America. |
| Infrastructure | ▬ Steady | Growing at company average when adjusted for Invacare. |
The New Operating Model: Leadership, Incentives & Structure
- COO appointment: Selvakumaran Mannappan, with over 29 years in IT services and prior COO experience at a tier-1 firm, was appointed Chief Operating Officer.
- Compensation reset: The incentive structure now compensates on both profitability and revenue, a shift from the prior revenue-only model. Hunting commissions for opening new accounts are attractive, and a long-term incentive plan combining cash LTI, ESOPs and stock has been introduced, pivoting the culture toward performance-based pay.
- Leadership build-out: A CEO for the Rest of the World geography has been offered and is expected to join by end-November or early December. A strategy officer and a growth officer (focused on partnerships, marketing, and analyst relationships) will also be hired, though not at the CXO level.
- Unified delivery structure: The new structure, in practice since April 1, is already showing benefits: EBITDA margins have improved from 14% last year to 15.8% this quarter even after absorbing the salary hike.
Gen AI, Capability & the Acquisition Question
- Gen AI training at scale: An initial cohort of 500 colleagues has been extended to cover all ~12,500 colleagues. A Gen AI Center of Excellence was established last quarter with Microsoft.
- Acquisition posture: No acquisition discussions are currently ongoing. Management will focus on organic growth for a couple more quarters, strengthen the balance sheet, and generate cash. Any future acquisition will be for strategic capability in a high-growth domain or a technology/service line like Gen AI or engineering, never for revenue aggregation. Cultural alignment is a non-negotiable criterion.
Guha: "We will never acquire a company for revenue aggregation or revenue growth, but that has to give us solid capability around the two domains or the two service lines that I spoke about."
People & Utilization
- Utilization band: Management is comfortable keeping utilization in a narrow band of 84% to 86%.
- Headcount outlook: FY24 will see a positive headcount addition, though headcount may not directly correlate with revenue growth due to automation and a drive toward nonlinear revenue.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin exit rate | Exit Q4 at 16% EBITDA | Q4 FY24 |
| Medium-term EBITDA range | 15.5% to 16.5%, possibly up to 17%, with 1–2% reinvested | Next 1–1.5 years |
| Q3 performance | Muted due to shorter quarter and furloughs; Q4 back to execution-led performance | Q3 FY24 / Q4 FY24 |
| Large deal revenue ramp | Revenue uptake from the $100 mn+ deal begins | April onwards |
| TCV ambition | Exit FY24 with higher total TCV than FY23 | FY24 exit |
| Acquisition timeline | No acquisition for a couple more quarters; then only strategic, capability-focused deals | Next 4–6 quarters |
| Furlough severity | Not seeing extended furlough requests; will be in the typical range, though higher than last year because BFSI is growing | Q3 FY24 |
| Headcount | Positive headcount addition for FY24 | FY24 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue (reported currency) | $158.3 million, +3% QoQ |
| Revenue (constant currency) | ₹15.91 crore, +3.1% QoQ |
| Revenue (INR) | ₹1,309.9 crore, +10% YoY |
| Revenue growth ex-Invacare | +4.4% QoQ and +13% YoY, excluding the one-time disengagement fee in Q1 |
| EBITDA margin | 15.8%, +50 bps QoQ; wage hikes of ~90 bps impact absorbed |
| EBITDA | $25 million, up from $23.5 million in Q1 |
| PAT margin | 11.1%, PAT of $17.5 million |
| Effective tax rate (full year expected) | ~25% |
| Large-deal TCV signed | $271 million, including one deal with TCV upwards of $100 million from a Fortune 500 client |
| TCV growth (past 9 months vs preceding 9 months) | +21% |
| BFSI vertical growth | +5.3% QoQ |
| Manufacturing vertical growth | +4.2% QoQ |
| Utilization | Above 86% |
| DSO days | 52 days |
| Cash and bank balances | $173.5 million, increased by $13.5 million QoQ |
| Operating cash flow to EBITDA | ~93% |
| Active client count | 278, reduced from 285 |
| Americas revenue share | 85% to 86% of overall revenues |
| Interim dividend | ₹2.50 per share, record date 8 November 2023 |